English | 繁體

Search in the results

UM

Browse/Search Results:  1-4 of 4 Help

Selected(0)Clear Items/Page:    Sort:
Cost-effectiveness of camrelizumab plus rivoceranib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma Journal article
Zou, Huimin, Lai, Yunfeng, Chen, Xianwen, Ung, Carolina Oi Lam, Hu, Hao. Cost-effectiveness of camrelizumab plus rivoceranib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma[J]. Therapeutic Advances in Gastroenterology, 2025, 18, 1-13.
Authors:  Zou, Huimin;  Lai, Yunfeng;  Chen, Xianwen;  Ung, Carolina Oi Lam;  Hu, Hao
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:3.9/4.0 | Submit date：2025/01/22
Camrelizumab  Cost-effectiveness Analysis  Hepatocellular Carcinoma  Partitioned Survival Model  Rivoceranib  
Real-world treatment patterns and outcomes for patients with advanced hepatocellular carcinoma initially treated with PD-1 inhibitors Journal article
Zou, Huimin, Ge, Ying, Chen, Wenge, Yao, Dongning, Oi Lam Ung, Carolina, Lai, Yunfeng, Hu, Hao. Real-world treatment patterns and outcomes for patients with advanced hepatocellular carcinoma initially treated with PD-1 inhibitors[J]. International Immunopharmacology, 2024, 132, 111947.
Authors:  Zou, Huimin;  Ge, Ying;  Chen, Wenge;  Yao, Dongning;  Oi Lam Ung, Carolina; et al.
Favorite | TC[WOS]:0 TC[Scopus]:1  IF:4.8/5.0 | Submit date：2024/05/16
Hepatocellular Carcinoma  Programmed Cell Death Protein-1 Inhibitor  Tislelizumab  Camrelizumab  China  
Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis Journal article
Wu, Hao Xiang, Pan, Yi Qian, He, Ye, Wang, Zi Xian, Guan, Wen Long, Chen, Yan Xing, Yao, Yi Chen, Shao, Ning Yi, Xu, Rui Hua, Wang, Feng. Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis[J]. Journal of Clinical Oncology, 2023, 41(9), 1735-1746.
Authors:  Wu, Hao Xiang;  Pan, Yi Qian;  He, Ye;  Wang, Zi Xian;  Guan, Wen Long; et al.
Favorite | TC[WOS]:35 TC[Scopus]:38  IF:42.1/37.4 | Submit date：2023/04/03
Pembrolizumab  Placebo  Camrelizumab  Nivolumab  Survival  Efficacy  Therapy  Safety  Chemo  
N-glycosylation of PD-1 promotes binding of camrelizumab Journal article
Liu,Kefang, Tan,Shuguang, Jin,Wanjun, Guan,Jiawei, Wang,Qingling, Sun,Huan, Qi,Jianxun, Yan,Jinghua, Chai,Yan, Wang,Zhongfu, Deng,Chuxia, Gao,George F.. N-glycosylation of PD-1 promotes binding of camrelizumab[J]. EMBO Reports, 2020, 21(12), e51444.
Authors:  Liu,Kefang;  Tan,Shuguang;  Jin,Wanjun;  Guan,Jiawei;  Wang,Qingling; et al.
Favorite | TC[WOS]:54 TC[Scopus]:60  IF:6.5/8.3 | Submit date：2021/03/02
Camrelizumab  Glycosylation  Monoclonal Antibody  Pd-1  Structure